Maxime Verhoeven

33 Systematic review of remission-induction strategies in early RA Conclusion Remission-induction strategies initiated in early RA patients are more effective in achieving remission compared to single csDMARD-initiating strategies. However, their benefit compared to that of a single csDMARD-initiating therapy strategy with GC bridging seems to be limited. REFERENCES 1. Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76 , 960–977 (2017). 2. Raza, K. & Filer, A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close ? Ann. Rheum. Dis. 74 , 793–794 (2015). 3. Singh, J. a et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68 , 1–26 (2015). 4. Bijlsma, J. W. J. et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388 , 343–355 (2016). 5. Dougados, M. et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann. Rheum. Dis. 76 , 88–95 (2017). 6. Teitsma, X. M. et al. Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors. Ann. Rheum. Dis. 77 , 1261–1267 (2018). 7. Ajeganova, S. & Huizinga, T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther. Adv. Musculoskelet. Dis. 9 , 249–262 (2017). 8. Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339 , b2700 (2009). 9. Higgins, J. P. T. et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343 , 1–9 (2011). 10. Higgins, J. P. T. & Green, S. (editors). Cochrane Handbook for Systematic Reviews of Interventions . (The Cochrane Collaboration, 2011, 2011). 11. Atsumi, T. et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann. Rheum. Dis. 75 , 75–83 (2016). 12. Burmester, G. R. et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann. Rheum. Dis. 75 , 1081–1091 (2016). 13. Dougados, M. R. et al. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). J. Rheumatol. 41 , 1922–1934 (2014). 14. Emery, P. et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD- naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Ann. Rheum. Dis. 76 , 96–104 (2017). 2